Screener
Corvus Pharmaceuticals CRVS Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Change in fair value of warrant liability | — | 25,129 |
| Loss before equity method investment | (13,093) | 15,732 |
| Loss from equity method investment | (599) | (539) |
| Net (loss) income | $(13,692) | $15,193 |
| Net (loss) income per share, basic | $(0.15) | $0.21 |
| Net loss per share, diluted | $(0.15) | $(0.13) |
| Shares used to compute net (loss) income per share, basic | 89,996,728 | 72,126,496 |
| Shares used to compute net loss per share, diluted | 89,996,728 | 75,152,514 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's net income?
- Corvus Pharmaceuticals (CRVS) reported net income of -$13.69M in Q1 2026.
- How has Corvus Pharmaceuticals's net income changed year-over-year?
- Corvus Pharmaceuticals's net income decreased by 190.1% year-over-year, from $15.19M to -$13.69M.
- What is the long-term trend for Corvus Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's net income has grown at a -22.9% compound annual growth rate (CAGR), from -$43.24M to -$15.28M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Corvus Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude